Loren Data's SAM Daily™

FBO DAILY ISSUE OF JUNE 17, 2011 FBO #3492
SOLICITATION NOTICE

65 -- Dressing Sponges - Technical/Company Requirements Response Document

Notice Date

6/15/2011
 

Notice Type

Combined Synopsis/Solicitation
 

NAICS

339112 — Surgical and Medical Instrument Manufacturing
 

Contracting Office

Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
 

ZIP Code

19111-5096
 

Solicitation Number

MW-1106-47_Dressing_Sponges
 

Point of Contact

Ricardo Orias, Phone: 619-532-8537, Cynthia Ingrao, Phone: (619) 532-8517
 

E-Mail Address

ricardo.orias.ctr@med.navy.mil, cynthia.ingrao.ctr.@med.navy.mil
(ricardo.orias.ctr@med.navy.mil, cynthia.ingrao.ctr.@med.navy.mil)
 

Small Business Set-Aside

N/A
 

Description

Responses to this RFIAQ should include all the information as indicated in the FBO. Please use this document for all your responses. The Defense Medical Materiel Program Office (DMMPO) Medical Materiel Enterprise Standardization Office (MMESO) announces a Request for Incentive Agreement Quotation (RFIAQ) for the standardization of Dressing Sponges. The MMESO West is the lead MMESO for this project. The primary objective of this program is to standardize the quality of care across the MMESO North, South, West, Pacific, Europe (hereafter referred to as MMESOs) areas of responsibility (AOR) and operational assemblages based on the critical balance of clinical efficacy and value. This Standardization Action (SA) will apply to all MMESOs. It is intended for this initiative to result in the standardization of a technically and clinically preferred product (s) and source for institutional and operational medicine requirements at the best possible price. It is intended for this initiative to result in the reduction of Stock Keeping Units (SKUs) and National Stock Numbers (NSN). It is also intended that standardized products be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program. As an enterprise-wide clinically driven program, vendors and products must meet specific technical requirements plus products must meet or exceed specific clinical performance requirements as a primary consideration. Among vendors who meet the technical requirements and the products that meet or exceed the clinical the clinical preferred threshold, best price will determine selection. It is intended that the selected vendor (s) for this SA support the enterprise goal of medical materiel standardization that combines operational and institutional requirements. The government is seeking a single award for this SA. The major facilities in the MMESOs include, but are not limited to MMESO North: Walter Reed Army Medical Center, National Naval Medical Center, Naval Medical Center Portsmouth, Wright-Patterson Medical Center; MMESO South: Wilford Hall Medical Center, Brooke Army Medical Center, Naval Hospital Jacksonville, Martin Army Community Hospital; MMESO West: Naval Medical Center San Diego, Madigan Army Medical Center, Irwin Army Community Hospital, Mike O'Callaghan Federal Hospital; MMESO Pacific: Tripler Army Medical Center, Honolulu, HI, 18th Medical Group, Kadena AB, Okinawa, US Naval Hospital, Yokosuka, Japan; MMESO Europe: Landstuhl Regional Medical Center, Landstuhl, GE, US Naval Hospital, Naples, Italy, the 48th Medical Group, Lakenheath, UK; and Operational U.S. Forces. This standardization action is part of the Medical/Surgical PV program executed by the Defense Logistics Agency (DLA) Troop Support, Directorate of Medical Materiel. To participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the current Med-Surg PV for each MMESOs Area of Responsibility (AOR), i.e., Cardinal Health, and Owens & Minor. This requirement is pursuant to the DAPA clause by which DAPA holders agree to the standardization process and agree to allow PVs to distribute their products. The Incentive Agreement (IA) resulting from this RFIAQ is a supplement to the PV Program and is not a contract. For additional information regarding DLA Troop Support Medical's PV program please access its web site at https://dmmonline.dscp.dla.mil This IA standardization initiative will be a Three Phase IPP Process: vendor (s) who meets the technical / company requirements in Phase I will be invited to advance and participate Phase II where no-charge products will be provided for clinical evaluation and Phase III where pricing will be required for submittal. Phase II and Phase III will be run concurrently. The resulting IA will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month "option" periods not to exceed a total of 5 years. Anticipated selection date is September 2011. The selection will be based on the product and vendor that provides the Best Value to the enterprise. Products and vendors that meet or exceed the technical and clinical performance requirements will be considered clinically preferred products and sources. Among vendors who meet the technical requirements and the products that meet or exceed the clinically preferred standard, best price (i.e. lowest Aggregate Post Standardization Cost) will determine selection. Point of Contact: Ricardo Orias, MMESO West Team Leader, Ricardo.orias.ctr@med.navy.mil,(619)532-8537; Cindy Ingrao, MMESO West Clinical Analyst, Cynthia.ingrao.ctr@med.navy.mil,(619) 532-8517;Cheryl Janus, MMESO West Clinical Analyst, Cheryl.janus.ctr@med.navy.mil,(619) 532-7554. B. Products & Performance Required The MMESOs are seeking product line items in the category of Dressing Sponges. Within the MMESOs, this product line has an estimated annual dollar requirement of $2,721,781. This forecast is based on historical Prime Vendor sales during a recent 12-month period. Based on the recent 12-month usage data, the top thirty six (36) line items of the total one hundred nine (109) line items, account for 81.8% ($2,226,508) of the total volume in sales ($2,721,781) in the MMESOs and are procurement significant. The top high volume usage lines for this project are shown in the Technical/Company Requirements below, consolidated by product type to reduce duplication within the top 7 lines. This represents the line item, or SKU, reduction that is an additional objective of this program. C. Instructions to Vendors A vendor interested in participating in this standardization initiative will provide an initial response to the FBO-posted RFIAQ to Ricardo Orias, MMESO West Team Leader, ricardo.orias.ctr@med.navy.mil, Ms. Cindy Ingrao, Clinical Analyst, cynthia.ingrao.ctr@med.navy.mil and Ms. Cheryl Janus, Clinical Analyst, cheryl.janus.ctr@med.navy.mil. The vendor's initial responses will include detailed information requested in the technical/company requirements and must also include: (1) Company name and address; (2) Company Point of Contact (POC) (Name and Phone Number, Fax Number, and E-mail address); and (3) Identification of the RFIAQ to which the vendor is responding. Due to the potential for e-mail to be lost in transmission, from network security, etc., vendor is strongly encouraged to confirm with the MMESO West that its initial submission, quote and literature actually arrived at the MMESO West via email. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. Vendor should complete and submit the attached document. Vendor who cannot open the attachments, may contact the POC as noted in the FBO RFIAQ before the COB on the date listed for closing and a copy will be provided to vendor via an alternate medium (fax, email or hard copy). A vendor who does not meet the deadline of COB 5:00 PM Pacific Standard Time (PST) on the date listed for closing, will be disqualified from further consideration in the standardization initiative. D. Source Selection Procedures The MMESO Joint Product Review Board (JPRB) will serve as the forum for clinical recommendations for product selection, seeking and evaluating opportunities for committed volume purchase agreements, and coordinating logistics efforts in support of DoD Components. The boards are chaired by Designated Senior Logisticians (DSLs) and co-chaired by Designated Senior Clinicians (DSCs) in the MMESO AORs and include clinicians and logisticians for Medical Treatment Facilities (MTFs) within each MMESO. The Clinical Advisory Committee (CAC) members are the deciding officials for this initiative. The MMESO DSLs and DSCs intend to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing based on committed volume of 80% of the total requirements of the MTFs in the MMESOs. The MMESO West reserves the right to conduct discussions and request revised quotes, if determined necessary. Phase I Technical / Company Requirements The MMESO CPT will review the responses from the vendors and determine which vendors meet the technical/company requirements and determine acceptability. Vendor must meet the technical requirements for continued consideration in this initiative. Vendor who does not meet the requirements will be disqualified. Failure to provide any requested information or meet any of the technical requirements will disqualify the vendor from further consideration. A vendor who meets the following technical/company requirements will be qualified/invited to participate in the clinical/performance selection and will be requested to submit their best product/price discount quotes via an email communication. All communications of significant acquisition milestones (such as invitations to participate, or notices of disqualification) should be digitally signed. Technical/Company Requirements: During the acquisition planning process, the MMESO CPT validated/approved the technical/company requirements outlined below. The four (4) requirements below must be answered with the vendor's initial submittal by the response date stated in the FBO announcement. A vendor who does not answer these requirements or provide documentation as needed to support these requirements will be disqualified in Phase I. 1. Vendor MUST provide a line of Dressing Sponges products that includes at a minimum the specific products identified below for sterile and non-sterile, woven, and latex free/safe Dressing Sponges in a variety of materials and widths as follows: a. GAUZE SPONGE, 8X4 12PLY BULK NONSTERILE GAUZE SPONGE, DRESSING, 4X4IN 8PLY NON-STERILE GAUZE SPONGE, DRESSING, 4X4IN 12PLY STERILE COVER SPONGE, RAYON/CELLULOSE, PEEL-BACK PKG, 4" X 4", STERILE GAUZE SPONGE, DRESSING, 2X2IN 8PLY STERILE SPONGE FLUFF MEDIUM 6X6 3/4IN DIAG 3" X 8", FINE MESH, STERILE * Operational usage items are included in this list of Dressing Sponges. b. Vendor MUST provide a complete itemized list of items supplied (manufacture and/or distribute by brands and descriptions) via excel sheet, and product catalog & literature in response to this RFIAQ with initial submittal. A vendor is required to supply all items listed in all sizes and device type. 3. Vendor MUST have a DAPA or be in the process of obtaining a DAPA for the Dressing Sponges product line. Vendor MUST provide DAPA number with initial submittal or provide documentation that DAPA has been applied for with response submittal. 4. Vendor MUST have agreements with the current Med/Surg Prime Vendors for each MMESO AOR, i.e. Cardinal Health and Owens & Minor for Dressing Sponges or be in the process of obtaining Prime Vendor agreements. Vendor must provide documentation to support agreements with initial submittal. 5. Vendor MUST submit discounts off of DAPA for all products included in this standardization initiative. Where lower FSS prices are available, DAPA holders are required by previous agreement to provide the FSS price as the DAPA price. Vendor shall not quote FSS prices as the discounted price for purposes of this standardization initiative. Phase II Acceptability Evaluation Clinical Performance Clinical Performance Requirements Following acceptability of the technical/company requirements, the MMESO West, on behalf of the CPT, will request product sample sets from the product group to be sent to the CPT members at the participating MTFs. Vendor will be given 30 calendar days from the issue of the notice in which to deliver the product samples for clinical evaluation at Phase II. Product samples must be shipped to arrive at the designated addresses by 5:00PM local time for each MTF on the 30th calendar day after the notice to ship. Vendor MUST be able to deliver product literature, training materials and evaluation samples to the MMESO Pacific via FedEx or UPS AND to the MMESO Europe via United States Postal Service (USPS) and throughout the United States when requested in Phase II. Vendor who cannot or does not meet this requirement will be disqualified from the standardization process. Vendor must send the MMESO West verification regarding the shipment of literature and samples. This information will include the date of shipment, final delivery date, tracking numbers and the carrier used by the vendor. Vendor will provide ONLY the following no cost product samples for clinical/performance evaluation. (Unused samples will not be returned). Two (2) packs of each type and size listed below are to be provided as samples to each of the evaluation sites as identified in the letters of invitation. Gauze Sponge Dressing, 4X4IN 8PLY Non-Sterile Gauze Sponge Dressing, 2X2IN 8PLY Sterile Gauze Sponge Dressing 4X4IN 12PLY Sterile Cover Sponge, Rayon/Cellulose, Peel-Pack4X4 Sterile Sponge Fluff Medium 6X6 3/4IN Diagnostic 3" X 8" Fine Mesh, Sterile The clinical/performance acceptability evaluation period will last for fourteen (14) calendar days. Each evaluator will evaluate each Dressing Sponge product sample from each vendor against the established requirements. A trial will consist of evaluating all sample products from a single vendor, evaluated against the requirements and recorded on a single evaluation form per vendor. The acceptability evaluation responses will be in a Likert scale format with a one (1) through five (5) scoring range. The scale descriptors are: one (1) - Completely Unacceptable, two (2) - Overwhelmingly Unacceptable, three (3) - Partially Unacceptable, four (4) - Acceptable, and five (5) - Highly Acceptable. The MMESO JPRB has established a 4.0 as the Clinically Preferred threshold of products for standardization. A vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. Of those vendors who are qualified as clinically preferred, selection will be based on best price. A vendor who has been disqualified or has not been selected will be notified in writing upon disqualification. Clinical /performance acceptability evaluations by the participating CPT facilities will be tabulated resulting in one score per participating MMESO per vendor. The participating MMESOs' scores by vendor will then be combined resulting in one final vendor performance evaluation score. All clinical/performance acceptability evaluations will be tabulated by the MMESO West, and results will be forwarded to the MMESO CPT for final review. There will be sixteen (16) MTFs enterprise wide that will be evaluating products. Clinical/Performance Requirements: During the acquisition planning process, the MMESO CPT validated/approved the clinical/performance requirements outlined below. 1. The dressing sponge does not lint/release fragments of material. (Patient Safety - NPSG #7 - 07.05.01) The weave and composition of the dressing sponge must remain securely intact. The release of woven material fragments can contribute to the formation of granulomas and/or act as a foreign body which may contribute to a Hospital Acquired Surgical Site infection. 2. The dressing sponge is composed of a soft and absorbable material. (Patient Safety/Comfort - NPSG 07.05.01) Product should be soft and absorbable reducing risk of tissue damage to patient. Abrasive materials can damage the skin and internal tissues and contribute to bleeding, abrade tissue and cause harm to surrounding tissue which results in an inflammatory response to the tissue damage. 3. The dressing sponge is durable and does not fray. (Patient Safety - NPSG-7.05.01) Product will have woven material which will maintain its shape and required construction. Sponges which do not retain durability and fray can be harmful to the tissue. 4. The packaging must be constructed allowing for immediate sterile opening during sterile procedure and allows for aseptic delivery to the sterile field. (Patient Safety and Efficiency of Usage) Package edges should separate easily and evenly. Packaging/containers which open unevenly can deliver a contaminated sponge to a sterile field. Phase III Pricing Analysis Price Analysis Upon completion of the Phase I - Technical/Company Requirements, a vendor who is found technically acceptable will be qualified /invited to provide product samples and price discount quotes concurrently. A vendor will be given 30 calendar days from the date of pricing requests, to submit IA pricing quotes, in a prescribed electronic spreadsheet format, based upon the requirements of the MMESOs. Pricing will be submitted to MMESO West by 5:00 PM PST, thirty (30) calendar days after the issue date of the vendor notice to submit best price quotes. Vendor quotes should contain the vendor's best product matches for the specific products requested in this announcement. The MMESO DSLs and DSCs intend to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing for the products identified in this announcement (based on committed volume of 80% of the total requirements of the MTFs in the MMESOs). Price will be analyzed based on the projected Aggregate Post-Standardization costs for each vendor. Aggregate Post-Standardization Cost will be calculated for each vendor by applying the vendor's offered prices to the anticipated annual usage of the enterprise. Unmatched items will be represented in the Post-Standardization Cost at a baseline non-discounted price (current DAPA price of product with highest procurement). Among the products and sources that were determined to be clinically preferred, the best price Aggregate Post-Standardization Cost will be selected.
 

Web Link

FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M/MW-1106-47_Dressing_Sponges/listing.html)
 

Place of Performance

Address: Medical Materiel Enterprise Standardization Office (MMESO) West, 34960 Bob Wilson Dr., San Diego, California, 92134, United States

Zip Code: 92134
 

Record

SN02474059-W 20110617/110615235316-46e2a588e02cf732d97ede4974b67b07 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |